Evaluation of cardiac toxicities in breast cancer patients treated with adjuvant chemotherapy and/or anti-her2 targeted agents: Late cardiac side-effects
L’hypothèse prédominante de cette thèse est que les traitements utilisés pour le cancer du sein de stade précoce (chimiothérapie avec des anthracyclines et/ou avec l’anticorps monoclonal trastuzumab) peuvent amener à des toxicités cardiaques à long terme, et qu’une évaluation de ce risque cardiaque...
Main Author: | De Azambuja, Evandro |
---|---|
Other Authors: | Piccart-Gebhart, Martine |
Format: | Doctoral Thesis |
Language: | en |
Published: |
Universite Libre de Bruxelles
2015
|
Subjects: | |
Online Access: | http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/221308 |
Similar Items
-
Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab
by: Rita De Sanctis, et al.
Published: (2021-06-01) -
Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity
by: Ibrahim Sadek, et al.
Published: (2017-09-01) -
Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study
by: Elena Geuna, et al.
Published: (2020-01-01) -
Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice
by: Yousif Nasser, et al.
Published: (2011-10-01) -
Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside
by: Mattan Levi, et al.
Published: (2020-12-01)